A new algorithm predicting imminent disease progression in advanced NSCLC patients by machine-learning integration of five serum biomarkers.

Kogan, Yuri; Kleiman, Marina; Shannon, Shmuel; Elishmereni, Moran; Taub, Eldad; Aptekar, L.; Brenner, Ronen; Berger, Raanan; Nechushtan, Hovav; Agur, Zvia

doi:10.1200/jco.2018.36.15_suppl.e21190

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the Kaplan-Meier survival curve, patients with 5-, 6-, or 7elevated pre-treatment tumor markers have short PFS compared to those with 0, 1-, 2-, 3-, or 4-elevated pre-treatment tumor markers. Therefore, clinicians/oncologists should consider the detection of the combined tumor markers before prescribing the chemotherapy (36)(37)(38). The role of chemotherapy in advanced-stage NSCLC in the past two decades has been well-established.…”

Section: Discussionmentioning

confidence: 99%

Clinical Evaluation of Serum Tumor Markers in Patients With Advanced-Stage Non-Small Cell Lung Cancer Treated With Palliative Chemotherapy in China

et al. 2020

View full text Add to dashboard Cite

This study aims to analyze the prognostic value of seven tumor makers and also investigate the response of palliative chemotherapy in advanced NSCLC patients with advanced disease. Methods: Medical records of 278 advanced NSCLC Chinese patients who received six cycles of palliative chemotherapy were retrospectively reviewed under ethical approval (JSCH2019K-011). Univariate and multivariate Cox regression analyses were performed using SPSS 24 to find the clinical value of these tumor markers and to identify the factors that were associated with progression-free survival (PFS), as well as the response to palliative chemotherapy. Results: In baseline characteristic, the high levels of CEA, CA-125, CA-199, AFP, NSE, CYFRA21-1, and CA15-3 were detected in 209 (75.18%), 139 (50.0%), 62 (22.30%), 18 (6.47%), 155 (55.75%), 176 (63.30%), and 180 (64.74%) patients, respectively. Univariate analysis revealed that patients with high vs. normal levels of all tumor markers had an increased risk of poor prognosis. In the multivariable Cox regression model, the patient with (high vs. normal) CYFRA21-1 levels (HR = 1.454, P = 0.009) demonstrated an increased poor PFS. However, patients with (high vs. normal) CA19-9 levels (HR = 0.524, P < 0.0001) and NSE levels (HR = 0.584, P < 0.0001) presented a decreased risk of PFS. Also, patients receiving 3-drugs regimen had better PFS compared to those on 2-drugs regimen (P = 0.043). Conclusions: The high levels of CYFRA21-1 was correlated with a poor prognostic factor of PFS for Advanced NSCLC patients. However, the high levels of CA19-9 and NSE were associated with a better prognostic factor of PFS. Additionally, smoking habits and tumor status had a poor prognostic factor of PFS. Moreover, we found that antiangiogenic therapy has high efficacy with first-line chemotherapy and longer PFS of NSCLC patients.

show abstract

Section: Discussionmentioning

confidence: 99%